Doxercalciferol - Sanofi
Alternative Names: 1 alpha-hydroxyergocalciferol; 1-alpha-D2; 1-alpha-Hydroxyvitamin D2; GZ-427397; Hectorol; TSA 870Latest Information Update: 31 Mar 2022
At a glance
- Originator University of Wisconsin at Milwaukee
- Developer Sanofi
- Class Calcium regulators; Ergocalciferols; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperparathyroidism
- Discontinued Breast cancer; Colorectal cancer; Plaque psoriasis; Postmenopausal osteoporosis; Prostate cancer
Most Recent Events
- 09 Apr 2021 Doxercalciferol is still in phase III trial for Hyperparathyroidism (In adolescents, In children) in USA (PO, Capsule) (NCT02859896)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 01 Dec 2016 Phase-III clinical trials in Hyperparathyroidism (In children, In adolescents) in USA (PO) (NCT02859896)